STLN
What one share of Starling Oncology holds
Services – Offices and Clinics of Doctors of Medicine
Formed in 2007, the business of what is now The Oncology Institute, Inc. ("TOI", the "Company", "we", or "our) and its affiliated professional corporations was created initially as a collection of community oncology practices in southern California, and has evolved to be a national leader in the pursuit of reducing the ever-rising cost of oncology care, while embracing clinical best practices, state-of-the-art technology, and compassionate treatment of patients.
Starling Oncology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.81 |
|---|---|
| Profit | −$0.30 |
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | −$0.03 |
| Cash and investments | $0.41 |
| Debt | $0.80 |
| Book value | −$0.25 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $3.17 | −$0.24 | $0.02 | −$0.01 | — | — |
| 2021 | $3.07 | −$0.16 | $0.04 | −$0.54 | — | $1.42 |
| 2022 | $3.13 | −$0.21 | $0.07 | −$0.83 | — | $1.68 |
| 2023 | $4.40 | −$0.92 | $0.06 | −$0.55 | — | $0.77 |
| 2024 | $5.24 | −$0.71 | $0.05 | −$0.40 | — | $0.05 |
| 2025 | $5.44 | −$0.54 | $0.03 | −$0.30 | — | −$0.16 |